MedPath

Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

Completed
Conditions
Hereditary Haemorrhagic Telangiectasia
Liver Transplant
Interventions
Other: Data collection from standard follow-up after liver transplant
Registration Number
NCT03942315
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Hereditary Hemorrhagic Telangiectasia (HHT) patient who underwent liver transplant for HHT
Read More
Exclusion Criteria
  • Patient who died in the year following transplantation
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Liver transplant in Hereditary Hemorrhagic TelangiectasiaData collection from standard follow-up after liver transplantHereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
Primary Outcome Measures
NameTimeMethod
Change in graft status after liver transplant for Hereditary Haemorrhagic Telangiectasia (HHT) (risk of recurrence)Every 6 months after transplantation up to 5 years

Recurrent clinical examinations (including laboratory, histological and radiological investigations)

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath